November 16, 2016 - By Hazel Jackson · 0 Comments
The stock of Stemcells Incorporated (NASDAQ:STEM) registered an increase of 10.03% in short interest. STEM’s total short interest was 1.93 million shares in November as published by FINRA. Its up 10.03% from 1.76M shares, reported previously. With 1.20M shares average volume, it will take short sellers 2 days to cover their STEM’s short positions. The short interest to Stemcells Incorporated’s float is 16.25%. About 8.37M shares traded hands or 967.56% up from the average. StemCells Inc (NASDAQ:STEM) has declined 62.85% since April 14, 2016 and is downtrending. It has underperformed by 67.53% the S&P500.
StemCells, Inc. is engaged in the research, development and commercialization of stem cell therapeutics. The company has a market cap of $22.02 million. The Firm is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. It currently has negative earnings. The Company’s lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.
Out of 4 analysts covering StemCells (NASDAQ:STEM), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. StemCells has been the topic of 5 analyst reports since September 2, 2015 according to StockzIntelligence Inc. H.C. Wainwright reinitiated the shares of STEM in a report on Tuesday, November 24 with “Buy” rating. Rodman & Renshaw reinitiated the stock with “Buy” rating in Wednesday, April 20 report. RBC Capital Markets maintained StemCells Inc (NASDAQ:STEM) on Wednesday, September 2 with “Buy” rating. The firm has “Hold” rating given on Tuesday, May 31 by Maxim Group. As per Wednesday, December 30, the company rating was maintained by H.C. Wainwright.
StemCells, Inc. (StemCells), incorporated on August 2, 1988, is engaged in the research, development and commercialization of stem cell therapeutics. The Firm is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company’s lead product development program is its central nervous system (CNS) Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system, which consists of the brain, spinal cord and eye.
More recent StemCells Inc (NASDAQ:STEM) news were published by: 247Wallst.com which released: “StemCells Reminds Investors of the Lessons of Outright Implosion” on May 31, 2016. Also Marketwatch.com published the news titled: “StemCells can’t fix its problems with a reverse split, or by burying bad news” on May 31, 2016. Bizjournals.com‘s news article titled: “Biotech with deficit, layoffs awards CEO $1 million severance package” with publication date: January 20, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson